Matthias Schott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Matthias Schott has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Werner Alfons Scherbaum
MVZ CardioCentrum Düsseldorf GmbH, Düsseldorf, Deutschland
5 shared publications - Anna Katharina Mundorf
Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, 40225 Düsseldorf, Germany
4 shared publications - Fritz Boege
Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, Heinrich Heine University, University Hospital, Moorenstraße 5, 40225 Düsseldorf, Germany
4 shared publications - Harald Heidecke
CellTrend Gmbh, Im Biotechnologiepark 3 TGZ II, 14943 Luckenwalde, Germany
4 shared publications - Jana Ruhrländer
Department of Cardiology, Angiology and Critical Care Medicine, Philipps University Marburg , Marburg
4 shared publications - Karin Schulze-Bosse
Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University, 40225 Düsseldorf, Germany
4 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 58 (02) , 56-52
Clinical Evaluation of a New Automated Bridge Assay for the Detection of Thyroid-Stimulating Hormone Receptor Autoantibodies
Graves’ disease is an autoimmune disease caused by autoantibodies to the thyroid-stimulating hormone receptor, which usually leads to hyperthyroidism in these patients. The aim of the present study was to evaluate a new automated bridge chemiluminescence thyroid-stimulating hormone receptor autoantibody assay for the diagnosis and in the follow-up of Graves’ disease patients and to compare this assay with another established competition assay. Altogether, 132 Graves’ disease, 39 autoimmune thyroiditis, 28 non-autoimmune nodular goiter and 27 thyroid cancer patients were included in this study. Receiver-operating characteristic plot analysis based on above mentioned samples revealed an area under the curve of 0.9994 (95% confidence interval: 0.9980–1.001), indicating high sensitivity and specificity of the assay. The optimal sensitivity (99.22%; 95% confidence interval: 95.7–99.8%) and specificity (98.98%; 95% confidence interval: 94.4%–99.8%) were seen at a cut-off level of 0.550 IU/L. The corresponding positive predictive value was 99.22%, whereas the negative predictive value was estimated to be 98.98%. A detailed comparison of the two assay systems used revealed a slightly different thyroid-stimulating hormone receptor autoantibody distribution with the new bridge assay detecting more thyroid-stimulating hormone receptor autoantibody-positive follow-up patients with active Graves’ disease compared with the competition assay. The measurement of thyroid-stimulating hormone receptor autoantibodies revealed a steady decline over the time of follow-up. In summary, our results demonstrate that the new automated bridge assay for detecting thyroid-stimulating hormone receptor autoantibodies has high sensitivity and specificity for diagnosing Graves’ disease and to discriminate from other thyroid diseases, respectively.
- 23 February 2026
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 58 (02) , 56-52
Open AccessClinical Evaluation of a New Automated Bridge Assay for the Detection of Thyroid-Stimulating Hormone Receptor Autoantibodies
Graves’ disease is an autoimmune disease caused by autoantibodies to the thyroid-stimulating hormone receptor, which usually leads to hyperthyroidism in these patients. The aim of the present study was to evaluate a new automated bridge chemiluminescence thyroid-stimulating hormone receptor autoantibody assay for the diagnosis and in the follow-up of Graves’ disease patients and to compare this assay with another established competition assay. Altogether, 132 Graves’ disease, 39 autoimmune thyroiditis, 28 non-autoimmune nodular goiter and 27 thyroid cancer patients were included in this study. Receiver-operating characteristic plot analysis based on above mentioned samples revealed an area under the curve of 0.9994 (95% confidence interval: 0.9980–1.001), indicating high sensitivity and specificity of the assay. The optimal sensitivity (99.22%; 95% confidence interval: 95.7–99.8%) and specificity (98.98%; 95% confidence interval: 94.4%–99.8%) were seen at a cut-off level of 0.550 IU/L. The corresponding positive predictive value was 99.22%, whereas the negative predictive value was estimated to be 98.98%. A detailed comparison of the two assay systems used revealed a slightly different thyroid-stimulating hormone receptor autoantibody distribution with the new bridge assay detecting more thyroid-stimulating hormone receptor autoantibody-positive follow-up patients with active Graves’ disease compared with the competition assay. The measurement of thyroid-stimulating hormone receptor autoantibodies revealed a steady decline over the time of follow-up. In summary, our results demonstrate that the new automated bridge assay for detecting thyroid-stimulating hormone receptor autoantibodies has high sensitivity and specificity for diagnosing Graves’ disease and to discriminate from other thyroid diseases, respectively.
- 29 December 2025
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 58 (02) , 43-49
Papillary Thyroid Carcinoma and Hashimoto’s Thyroiditis: New Insights into the Immunological Link
Hashimoto’s thyroiditis is the most common autoimmune disease, which is characterized by a cellular immune response with lymphatic infiltration of the thyroid gland mainly by T cells and B cells as well as by a humoral immune response leading to specific antibody production. Papillary thyroid carcinoma, the most common endocrine malignancy, is also characterized by broad immune cell infiltration. In recent years, a growing body of evidence has suggested a close connection between papillary thyroid carcinoma and Hashimoto’s thyroiditis. The mechanisms underlying the relationship between Hashimoto’s thyroiditis and papillary thyroid carcinoma, however, remain incompletely understood. One hallmark in the understanding of the immunological link between both diseases was the description of identical epitope-specific cytotoxic T cells as clear evidence for a close connection between Hashimoto’s thyroiditis und papillary thyroid carcinoma. In this review, we describe the role of Hashimoto’s thyroiditis in the development and prognosis of papillary thyroid cancer, the role of thyroid-specific antibodies in the diagnosis and outcome prediction of papillary thyroid carcinoma and the potential implication of this knowledge for cancer immunotherapy in general.
- 29 December 2025
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 58 (02) , 43-49
Papillary Thyroid Carcinoma and Hashimoto’s Thyroiditis: New Insights into the Immunological Link
Hashimoto’s thyroiditis is the most common autoimmune disease, which is characterized by a cellular immune response with lymphatic infiltration of the thyroid gland mainly by T cells and B cells as well as by a humoral immune response leading to specific antibody production. Papillary thyroid carcinoma, the most common endocrine malignancy, is also characterized by broad immune cell infiltration. In recent years, a growing body of evidence has suggested a close connection between papillary thyroid carcinoma and Hashimoto’s thyroiditis. The mechanisms underlying the relationship between Hashimoto’s thyroiditis and papillary thyroid carcinoma, however, remain incompletely understood. One hallmark in the understanding of the immunological link between both diseases was the description of identical epitope-specific cytotoxic T cells as clear evidence for a close connection between Hashimoto’s thyroiditis und papillary thyroid carcinoma. In this review, we describe the role of Hashimoto’s thyroiditis in the development and prognosis of papillary thyroid cancer, the role of thyroid-specific antibodies in the diagnosis and outcome prediction of papillary thyroid carcinoma and the potential implication of this knowledge for cancer immunotherapy in general.
- Open Access
- 29 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (11) , 2479
Exploring the Spectrum of Comorbidities Associated with Primary Aldosteronism: Insights from a Large Real-World Case-Control Study
Background: Primary aldosteronism (PA) is a common cause of endocrine hypertension, characterized by excessive aldosterone secretion leading to hypertension, hypokalemia, and metabolic alkalosis. While historically diagnosed based on this classic triad of symptoms, current understanding reveals a more nuanced presentation. This study aimed to investigate the prevalence of PA-associated diseases in a large German population. Methods: Medical records from the IQVIATM Disease Analyzer database were analyzed retrospectively. PA patients (n = 860) were matched with non-PA individuals (n = 4300) by age and sex. Associations between PA and predefined chronic diseases were examined using multivariable logistic regression. Results: PA was significantly associated with hypokalemia (7.8% vs. 1.6%, odds ratio (OR): 3.45; 95% confidence intervals (CIs): 2.41–4.96), hypertension (56.1% vs. 28.5%; OR: 2.37; 95% CIs: 2.00–2.81), hepatic steatosis (11.3% vs. 3.0%; OR: 1.85; 95% CIs: 1.34–2.57), gout (8.3% vs. 2.2%; OR: 1.64; 95% CIs: 1.15–2.35), chronic kidney disease (6.3% vs. 2.2%; OR: 1.59; 95% CIs: 1.10–2.31), diabetes mellitus not otherwise specified (7.9% vs. 2.9%; OR: 1.49; 95% CIs: 1.06–2.09), obesity (13.5% vs. 5.1%; OR: 1.38; 95% CIs: 1.05–1.82), and depression (14.8% vs. 6.2%; OR: 1.37; 95% CIs: 1.07–1.77). Conclusions: While the study design had limitations, including reliance on ICD codes for diagnosis, these findings underscore the critical need for early detection and personalized management strategies for PA to reduce associated risks and improve patient outcomes.
- 29 October 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (11) , 2479
Open AccessExploring the Spectrum of Comorbidities Associated with Primary Aldosteronism: Insights from a Large Real-World Case-Control Study
Background: Primary aldosteronism (PA) is a common cause of endocrine hypertension, characterized by excessive aldosterone secretion leading to hypertension, hypokalemia, and metabolic alkalosis. While historically diagnosed based on this classic triad of symptoms, current understanding reveals a more nuanced presentation. This study aimed to investigate the prevalence of PA-associated diseases in a large German population. Methods: Medical records from the IQVIATM Disease Analyzer database were analyzed retrospectively. PA patients (n = 860) were matched with non-PA individuals (n = 4300) by age and sex. Associations between PA and predefined chronic diseases were examined using multivariable logistic regression. Results: PA was significantly associated with hypokalemia (7.8% vs. 1.6%, odds ratio (OR): 3.45; 95% confidence intervals (CIs): 2.41–4.96), hypertension (56.1% vs. 28.5%; OR: 2.37; 95% CIs: 2.00–2.81), hepatic steatosis (11.3% vs. 3.0%; OR: 1.85; 95% CIs: 1.34–2.57), gout (8.3% vs. 2.2%; OR: 1.64; 95% CIs: 1.15–2.35), chronic kidney disease (6.3% vs. 2.2%; OR: 1.59; 95% CIs: 1.10–2.31), diabetes mellitus not otherwise specified (7.9% vs. 2.9%; OR: 1.49; 95% CIs: 1.06–2.09), obesity (13.5% vs. 5.1%; OR: 1.38; 95% CIs: 1.05–1.82), and depression (14.8% vs. 6.2%; OR: 1.37; 95% CIs: 1.07–1.77). Conclusions: While the study design had limitations, including reliance on ICD codes for diagnosis, these findings underscore the critical need for early detection and personalized management strategies for PA to reduce associated risks and improve patient outcomes.
- Open Access
Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS)
Post-acute COVID-19 vaccination syndrome (PACVS) is a chronic disease triggered by SARS-CoV-2 vaccination (estimated prevalence 0.02%). PACVS is discriminated from the normal post-vaccination state by altered receptor antibodies, most notably angiotensin II type 1 and alpha-2B adrenergic receptor antibodies. Here, we investigate the clinical phenotype using a study registry encompassing 191 PACVS-affected persons (159 females/32 males; median ages: 39/42 years). Unbiased clustering (modified Jaccard index) of reported symptoms revealed a prevalent cross-cohort symptomatology of malaise and chronic fatigue (>80% of cases). Overlapping clusters of (i) peripheral nerve dysfunction, dysesthesia, motor weakness, pain, and vasomotor dysfunction; (ii) cardiovascular impairment; and (iii) cognitive impairment, headache, and visual and acoustic dysfunctions were also frequently represented. Notable abnormalities of standard serum markers encompassing increased interleukins 6 and 8 (>80%), low free tri-iodine thyroxine (>80%), IgG subclass imbalances (>50%), impaired iron storage (>50%), and increased soluble neurofilament light chains (>30%) were not associated with specific symptoms. Based on these data, 131/191 participants fit myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and simultaneously also several other established dysautonomia syndromes. Furthermore, 31/191 participants fit none of these syndromes. In conclusion, PACVS could either be an outlier of ME/CFS or a dysautonomia syndrome sui generis.
Open AccessClinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS)
Post-acute COVID-19 vaccination syndrome (PACVS) is a chronic disease triggered by SARS-CoV-2 vaccination (estimated prevalence 0.02%). PACVS is discriminated from the normal post-vaccination state by altered receptor antibodies, most notably angiotensin II type 1 and alpha-2B adrenergic receptor antibodies. Here, we investigate the clinical phenotype using a study registry encompassing 191 PACVS-affected persons (159 females/32 males; median ages: 39/42 years). Unbiased clustering (modified Jaccard index) of reported symptoms revealed a prevalent cross-cohort symptomatology of malaise and chronic fatigue (>80% of cases). Overlapping clusters of (i) peripheral nerve dysfunction, dysesthesia, motor weakness, pain, and vasomotor dysfunction; (ii) cardiovascular impairment; and (iii) cognitive impairment, headache, and visual and acoustic dysfunctions were also frequently represented. Notable abnormalities of standard serum markers encompassing increased interleukins 6 and 8 (>80%), low free tri-iodine thyroxine (>80%), IgG subclass imbalances (>50%), impaired iron storage (>50%), and increased soluble neurofilament light chains (>30%) were not associated with specific symptoms. Based on these data, 131/191 participants fit myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and simultaneously also several other established dysautonomia syndromes. Furthermore, 31/191 participants fit none of these syndromes. In conclusion, PACVS could either be an outlier of ME/CFS or a dysautonomia syndrome sui generis.
- Open Access
- 12 June 2024
- Published by MDPI AG in Preprints.org
Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS)
Post-acute COVID-19 vaccination syndrome (PACVS) is distinguished from the normal post-vaccination state by altered receptor antibodies (Semmler et al. Vaccines 2023, 11, 1642). Here, we explore the symptoms registry and standard serum markers acquired in the above study to delineate the disease phenotype of PACVS. Symptoms reported by the participants overlapped with established complex dysautonomia syndromes (ME/CFS, POTS, MCAS, SFN). However, many participants were qualified for several (131/191) or none (31/191) of these syndromes. Unbiased clustering (modified Jaccard index) revealed a prevalent cross-cohort symptomatology of malaise and chronic fatigue (> 80% of cases). Overlapping clusters of (i) peripheral nerve dysfunction, dysesthesia, motor weakness, pain, vasomotor dysfunction, (ii) cardiovascular impairment, and (iii) cognitive impairment, headache, optic, oculo-motoric and acoustic dysfunctions were also frequently represented. Conspicuous serum markers encompassed increases in interleukins 6 and 8 and low fT3 levels (> 80%), IgG-subclass imbalances and impaired iron-storage (> 50%), and increases in sNFL (> 30%). Serum markers were not correlated to specific symptoms or symptom clusters. A single and unique cause (i. e. SARS-CoV-2 vaccination) is improbable to trigger several distinct etiologies. Therefore, the symptoms and serological features observed in our study cohort probably represent facets of a single complex syndrome.
- 12 June 2024
- Published by MDPI AG in Preprints.org
Open AccessClinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS)
Post-acute COVID-19 vaccination syndrome (PACVS) is distinguished from the normal post-vaccination state by altered receptor antibodies (Semmler et al. Vaccines 2023, 11, 1642). Here, we explore the symptoms registry and standard serum markers acquired in the above study to delineate the disease phenotype of PACVS. Symptoms reported by the participants overlapped with established complex dysautonomia syndromes (ME/CFS, POTS, MCAS, SFN). However, many participants were qualified for several (131/191) or none (31/191) of these syndromes. Unbiased clustering (modified Jaccard index) revealed a prevalent cross-cohort symptomatology of malaise and chronic fatigue (> 80% of cases). Overlapping clusters of (i) peripheral nerve dysfunction, dysesthesia, motor weakness, pain, vasomotor dysfunction, (ii) cardiovascular impairment, and (iii) cognitive impairment, headache, optic, oculo-motoric and acoustic dysfunctions were also frequently represented. Conspicuous serum markers encompassed increases in interleukins 6 and 8 and low fT3 levels (> 80%), IgG-subclass imbalances and impaired iron-storage (> 50%), and increases in sNFL (> 30%). Serum markers were not correlated to specific symptoms or symptom clusters. A single and unique cause (i. e. SARS-CoV-2 vaccination) is improbable to trigger several distinct etiologies. Therefore, the symptoms and serological features observed in our study cohort probably represent facets of a single complex syndrome.
- 15 April 2024
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 56 (06) , 424-428
Thyroglobulin Antibodies and Tumor Epitope-Specific Cellular Immunity in Papillary Thyroid Cancer
Papillary thyroid carcinoma (PTC) is characterized by T cell infiltration and frequently by the presence of anti-thyroglobulin antibodies (TgAbs). The role of cellular immunity and of TbAbs in this context is a matter of debate. The aim of our study was to correlate the presence of TgAbs, tumor epitope-specific T cells and the clinical outcome of PTC patients. We studied n=183 consecutive patients with a diagnosis of PTC which were treated with total thyroidectomy plus 131I ablation. During a follow-up of in mean 97 months, most of the PTC patients had no signs of tumor relapse (n=157 patients). In contrast, one patient had serum Tg levels above the detection limit and<1 ng/ml, two patients Tg serum levels≥1 ng/ml and<2 ng/ml and n=23 patients had Tg serum levels≥2 ng/ml. Morphological signs of tumor recurrence were seen in 14 patients; all of these patients had serum Tg levels≥2 ng/ml. Importantly, with the exception of one patient, all TgAb positive PTC patients (n=27) had no signs of tumor recurrence as the serum Tg levels were below the assays functional sensitivities. Tetramer analyses revealed a higher number of tumor epitope-specific CD8+T cells in TgAb positive patients compared to TgAb negative PTC patients. In summary, we show that the occurrence of TgAbs may have an impact on the clinical outcome in PTC patients. This might be due to a tumor epitope-specific cellular immunity in PTC patients. Received: 14 February 2024 Accepted: 26 February 2024 Article published online: 15 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 15 April 2024
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 56 (06) , 424-428
Thyroglobulin Antibodies and Tumor Epitope-Specific Cellular Immunity in Papillary Thyroid Cancer
Papillary thyroid carcinoma (PTC) is characterized by T cell infiltration and frequently by the presence of anti-thyroglobulin antibodies (TgAbs). The role of cellular immunity and of TbAbs in this context is a matter of debate. The aim of our study was to correlate the presence of TgAbs, tumor epitope-specific T cells and the clinical outcome of PTC patients. We studied n=183 consecutive patients with a diagnosis of PTC which were treated with total thyroidectomy plus 131I ablation. During a follow-up of in mean 97 months, most of the PTC patients had no signs of tumor relapse (n=157 patients). In contrast, one patient had serum Tg levels above the detection limit and<1 ng/ml, two patients Tg serum levels≥1 ng/ml and<2 ng/ml and n=23 patients had Tg serum levels≥2 ng/ml. Morphological signs of tumor recurrence were seen in 14 patients; all of these patients had serum Tg levels≥2 ng/ml. Importantly, with the exception of one patient, all TgAb positive PTC patients (n=27) had no signs of tumor recurrence as the serum Tg levels were below the assays functional sensitivities. Tetramer analyses revealed a higher number of tumor epitope-specific CD8+T cells in TgAb positive patients compared to TgAb negative PTC patients. In summary, we show that the occurrence of TgAbs may have an impact on the clinical outcome in PTC patients. This might be due to a tumor epitope-specific cellular immunity in PTC patients. Received: 14 February 2024 Accepted: 26 February 2024 Article published online: 15 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
Chronic Fatigue and Dysautonomia following COVID-19 Vaccination Is Distinguished from Normal Vaccination Response by Altered Blood Markers
SARS-CoV-2 mRNA vaccination can entail chronic fatigue/dysautonomia tentatively termed post-acute COVID-19 vaccination syndrome (PACVS). We explored receptor autoantibodies and interleukin-6 (IL-6) as somatic correlates of PACVS. Blood markers determined before and six months after first-time SARS-CoV-2 vaccination of healthy controls (N = 89; 71 females; mean/median age: 39/49 years) were compared with corresponding values of PACVS-affected persons (N = 191; 159 females; mean/median age: 40/39 years) exhibiting chronic fatigue/dysautonomia (≥three symptoms for ≥five months after the last SARS-CoV-2 mRNA vaccination) not due to SARS-CoV-2 infection and/or confounding diseases/medications. Normal vaccination response encompassed decreases in 11 receptor antibodies (by 25–50%, p < 0.0001), increases in two receptor antibodies (by 15–25%, p < 0.0001) and normal IL-6. In PACVS, serological vaccination–response appeared significantly (p < 0.0001) altered, allowing discrimination from normal post-vaccination state (sensitivity = 90%, p < 0.0001) by increased Angiotensin II type 1 receptor antibodies (cut-off ≤ 10.7 U/mL, ROC-AUC = 0.824 ± 0.027), decreased alpha-2B adrenergic receptor antibodies (cut-off ≥ 25.2 U/mL, ROC-AUC = 0.828 ± 0.025) and increased IL-6 (cut-off ≤ 2.3 pg/mL, ROC-AUC = 0.850 ± 0.022). PACVS is thus indicated as a somatic syndrome delineated/detectable by diagnostic blood markers.
Open AccessChronic Fatigue and Dysautonomia following COVID-19 Vaccination Is Distinguished from Normal Vaccination Response by Altered Blood Markers
SARS-CoV-2 mRNA vaccination can entail chronic fatigue/dysautonomia tentatively termed post-acute COVID-19 vaccination syndrome (PACVS). We explored receptor autoantibodies and interleukin-6 (IL-6) as somatic correlates of PACVS. Blood markers determined before and six months after first-time SARS-CoV-2 vaccination of healthy controls (N = 89; 71 females; mean/median age: 39/49 years) were compared with corresponding values of PACVS-affected persons (N = 191; 159 females; mean/median age: 40/39 years) exhibiting chronic fatigue/dysautonomia (≥three symptoms for ≥five months after the last SARS-CoV-2 mRNA vaccination) not due to SARS-CoV-2 infection and/or confounding diseases/medications. Normal vaccination response encompassed decreases in 11 receptor antibodies (by 25–50%, p < 0.0001), increases in two receptor antibodies (by 15–25%, p < 0.0001) and normal IL-6. In PACVS, serological vaccination–response appeared significantly (p < 0.0001) altered, allowing discrimination from normal post-vaccination state (sensitivity = 90%, p < 0.0001) by increased Angiotensin II type 1 receptor antibodies (cut-off ≤ 10.7 U/mL, ROC-AUC = 0.824 ± 0.027), decreased alpha-2B adrenergic receptor antibodies (cut-off ≥ 25.2 U/mL, ROC-AUC = 0.828 ± 0.025) and increased IL-6 (cut-off ≤ 2.3 pg/mL, ROC-AUC = 0.850 ± 0.022). PACVS is thus indicated as a somatic syndrome delineated/detectable by diagnostic blood markers.
- Open Access
- 4 September 2023
- Published by MDPI AG in Preprints.org
Chronic Fatigue and Dis-Autonomy following COVID-19 Vaccination is Distinguished from Normal Vaccination Response by Altered Blood Markers
SARS-CoV-2 mRNA vaccination can entail chronic fatigue/dis-autonomy tentatively termed post-acute COVID-19 vaccination syndrome (PACVS). We explored receptor autoantibodies and interleukin-6 (IL-6) as somatic correlates of PACVS. Blood markers determined before and six months after first-time SARS-CoV-2-vaccination of healthy controls (N = 89, 71 females, mean/ median age 39/ 49 years) were compared with corresponding values of PACVS-affected persons (N= 191, 159 females, mean/median age: 40/39 years) exhibiting chronic fatigue/dis-autonomy (≥ three symptoms for ≥ five months after last SARS-CoV-2 mRNA vaccination) not due to SARS-CoV-2 infection and/or confounding diseases/medications. Normal vaccination response encompassed decreases of 11 receptor-antibodies (by 25 - 50 %, p < 0.0001), increases in two receptor-antibodies (by 15 - 25 %, p < 0.0001) and normal IL-6. In PACVS, serological vaccination-response appeared significantly (p < 0.0001) altered, allowing discrimination from normal post-vaccination state (sensitivity = 90%, p < 0.0001) by increased angiotensin II type 1 receptor antibodies (cut-off ≤ 10.7 U/ml, ROC-AUC = 0.824 ± 0.027), decreased alpha-2B adrenergic receptor antibodies (cut-off ≥ 25.2 U/ml, ROC-AUC = 0.828 ± 0.025) and increased IL-6 (cut-off ≤ 2.3 pg/ml, ROC-AUC = 0.850 ± 0.022). PACVS is thus indicated as a somatic syndrome delineated/detectable by diagnostic blood markers
- 4 September 2023
- Published by MDPI AG in Preprints.org
Open AccessChronic Fatigue and Dis-Autonomy following COVID-19 Vaccination is Distinguished from Normal Vaccination Response by Altered Blood Markers
SARS-CoV-2 mRNA vaccination can entail chronic fatigue/dis-autonomy tentatively termed post-acute COVID-19 vaccination syndrome (PACVS). We explored receptor autoantibodies and interleukin-6 (IL-6) as somatic correlates of PACVS. Blood markers determined before and six months after first-time SARS-CoV-2-vaccination of healthy controls (N = 89, 71 females, mean/ median age 39/ 49 years) were compared with corresponding values of PACVS-affected persons (N= 191, 159 females, mean/median age: 40/39 years) exhibiting chronic fatigue/dis-autonomy (≥ three symptoms for ≥ five months after last SARS-CoV-2 mRNA vaccination) not due to SARS-CoV-2 infection and/or confounding diseases/medications. Normal vaccination response encompassed decreases of 11 receptor-antibodies (by 25 - 50 %, p < 0.0001), increases in two receptor-antibodies (by 15 - 25 %, p < 0.0001) and normal IL-6. In PACVS, serological vaccination-response appeared significantly (p < 0.0001) altered, allowing discrimination from normal post-vaccination state (sensitivity = 90%, p < 0.0001) by increased angiotensin II type 1 receptor antibodies (cut-off ≤ 10.7 U/ml, ROC-AUC = 0.824 ± 0.027), decreased alpha-2B adrenergic receptor antibodies (cut-off ≥ 25.2 U/ml, ROC-AUC = 0.828 ± 0.025) and increased IL-6 (cut-off ≤ 2.3 pg/ml, ROC-AUC = 0.850 ± 0.022). PACVS is thus indicated as a somatic syndrome delineated/detectable by diagnostic blood markers
- 7 April 2023
- Published by Elsevier in Clinical Imaging
- Vol. 99, 25-30
Contrast medium free selective adrenal vein sampling in the management of primary aldosteronism
- 7 April 2023
- Published by Elsevier in Clinical Imaging
- Vol. 99, 25-30
Contrast medium free selective adrenal vein sampling in the management of primary aldosteronism
- Open Access
Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors—A Retrospective Multi-Center Registry Analysis
Background: RET (rearranged during transfection) variants are the most prevalent oncogenic events in medullary thyroid cancer (MTC). In advanced disease, multi-tyrosine kinase inhibitors (MKIs) cabozantinib and vandetanib are the approved standard treatment irrespective of RET status. The actual outcome of patients with RET-positive MTC treated with MKIs is ill described. Methods: We here retrospectively determined the RET oncogene variant status with a targeted DNA Custom Panel in a prospectively collected cohort of 48 patients with advanced MTC treated with vandetanib and/or cabozantinib at four German referral centers. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan-Meier method. Results: In total, 44/48 (92%) patients had germline or somatic RET variants. The M918T variant was found in 29/44 (66%) cases. In total, 2/32 (6%) patients with a somatic RET variant had further somatic variants, while in 1/32 (3%) patient with a germline RET variant, additional variants were found. Only 1/48 (2%) patient had a pathogenic HRAS variant, and no variants were found in 3 cases. In first-line treatment, the median OS was 53 (95% CI (95% confidence interval), 32–NR (not reached); n = 36), and the median PFS was 21 months (12–39; n = 33) in RET-positive MTC patients. In second-line treatment, the median OS was 18 (13–79; n = 22), and the median PFS was 3.5 months (2–14; n = 22) in RET-positive cases. Conclusions: RET variants were highly prevalent in patients with advanced MTC. The treatment results in RET-positive cases were similar to those reported in unselected cohorts.
Open AccessTreatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitors—A Retrospective Multi-Center Registry Analysis
Background: RET (rearranged during transfection) variants are the most prevalent oncogenic events in medullary thyroid cancer (MTC). In advanced disease, multi-tyrosine kinase inhibitors (MKIs) cabozantinib and vandetanib are the approved standard treatment irrespective of RET status. The actual outcome of patients with RET-positive MTC treated with MKIs is ill described. Methods: We here retrospectively determined the RET oncogene variant status with a targeted DNA Custom Panel in a prospectively collected cohort of 48 patients with advanced MTC treated with vandetanib and/or cabozantinib at four German referral centers. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan-Meier method. Results: In total, 44/48 (92%) patients had germline or somatic RET variants. The M918T variant was found in 29/44 (66%) cases. In total, 2/32 (6%) patients with a somatic RET variant had further somatic variants, while in 1/32 (3%) patient with a germline RET variant, additional variants were found. Only 1/48 (2%) patient had a pathogenic HRAS variant, and no variants were found in 3 cases. In first-line treatment, the median OS was 53 (95% CI (95% confidence interval), 32–NR (not reached); n = 36), and the median PFS was 21 months (12–39; n = 33) in RET-positive MTC patients. In second-line treatment, the median OS was 18 (13–79; n = 22), and the median PFS was 3.5 months (2–14; n = 22) in RET-positive cases. Conclusions: RET variants were highly prevalent in patients with advanced MTC. The treatment results in RET-positive cases were similar to those reported in unselected cohorts.